Clinical Trial Update: A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan) [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating daily valdecoxib at 5 mg, 10 mg, and 20 mg versus placebo in knee osteoarthritis (Japan); completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• Valdecoxib (valdecoxib)

Snippet

Sponsor: Pfizer | Conditions: Osteoarthritis, Knee | Phase 2 | Status: COMPLETED